؉ cell selection of PBPC after harvest from G-CSF-treated allogeneic donors results in a more than 200-fold depletion of T lymphocytes in the graft and has been used to reduce the incidence of acute GVHD post transplant. Since transplantation with T cell-depleted BM grafts is associated with a delay in immune reconstitution and an increase of opportunistic infections, we evaluated the immunological reconstitution of patients with hematologic malignancies after therapy followed by CD34
The success of allogeneic hematopoietic stem cell transplantation for the treatment of hematologic malignancies is dependent on efficient eradication of the malignant clone and on the reconstitution of the host's hematopoiesis and immune system. All of these aspects are connected to the cellular composition of the graft, which differs greatly depending on the source used. The number of T lymphocytes transfused in PBPC grafts is several fold higher compared with bone marrow. While PBPC grafts appear to facilitate a more rapid engraftment when compared with BMT, [1] [2] [3] [4] the high number of T cells in the former raises concern with respect to an increased rate of acute GVHD, although this has not been consistently observed. The feasibility of CD34 ϩ selected allografting with respect to engraftment and a low incidence of severe acute GVHD has been demonstrated by several groups, including ours. 5, 6 Since T cell depletion of bone marrow grafts is associated with a delay of the reconstitution of the immune system and an increase in opportunistic infections after transplant, 7, 8 we analyzed the lymphocyte reconstitution and the incidence of infectious complications in patients after transplantation with CD34
ϩ -selected PBPC grafts from matched related donors. These data were compared to those obtained from patients who received either unselected PBPC or bone marrow during the same observation period. Factors that potentially affect immune reconstitution were analyzed.
Patients and methods

Patients
Forty-seven patients, who underwent allogeneic transplantation with CD34
ϩ -selected PBPC (PBPC34, n = 12), unselected PBPC (PBPC, n = 20), or BM (BMT, n = 15) from matched related donors at our institution between July 1994 and April 1997, were consecutively enrolled in the present study. Patient characteristics are shown in Table 1 . Patients with the following diagnoses fulfilled established criteria for the indication of allogeneic transplantation: AML or ALL, CML, myelodysplastic syndrome (MDS), progressive non-Hodgkin's lymphoma or multiple myeloma. Patients with advanced hematologic malignancies, who met the criteria for allogeneic transplantation and the criteria of a phase I/II trial protocol at our institution (Ͻ55 years of age, suffering from AML/ALL in second or further remission or primary refractory disease, refractory myelo- (20) 6 (40) ϩ CP = chronic phase; MM = multiple myeloma; NHL = non-Hodgkin's lymphoma; HD = Hodgkin's disease; *favorable = CR1, CP1; unfavorable = all other; Bu/Cy = busulfan/cyclophosphamide; VP16 = vepeside; TBI = total body irradiation. dysplastic syndrome (MDS), CML in accelerated phase, Ͼ1 chronic phase or progressive or relapsed lymphoma), were eligible for PBPC34 transplantation after written consent. 5 
Donors and grafts
All donors were HLA-identical siblings (one identical twin in the PBPC group). PBPC were mobilized with human recombinant G-CSF subcutaneously twice daily (Filgrastim, Amgen, Germany, 10-13.5 g/kg body weight) and leukapheresis was started on day 4. 9 For positive selection of CD34 ϩ cells, the leukapheresis product was directly processed using a Ceprate SC system (Cell Pro, Bothell, WA, USA) as reported earlier. 5 BM was collected under general anesthesia according to standard methods without the use of growth factors.
Supportive care, conditioning regimen, growth factors and GVHD prophylaxis
The conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg), except for patients with ALL or refractory disease, who were treated with total body irradiation (TBI, 12 Gy), cyclophosphamide (100 mg/kg) with or without VP-16 (50 mg/kg) as detailed in Table 1 . After engraftment, patients were monitored weekly by polymerase chain reaction (PCR) for the detection of cytomegalovirus (CMV) in the peripheral blood and pre-emptive treatment with ganciclovir (5 mg/kg every 12 h for 5 days, then every 24 h) or foscarnet (60 mg/kg every 12 h for 14 days, thereafter every 24 h) was started after two consecutive positive PCR results. 10 Treatment was continued until negative PCR results were obtained. GVHD prophylaxis consisted of cyclosporin A only (CsA; from day Ϫ3: 2.5 mg/kg twice daily, target trough level 200-350 ng/ml) for all patients in the PBPC34 group. Patients in the PBPC and BMT groups received CsA and methylprednisolone 11 (MP; from day ϩ7: 0.5 mg/kg/day; from day ϩ15: 1 mg/kg/day) or CsA and a short course of MTX (day ϩ1: 15 mg/m 2 ; days ϩ3 and ϩ6: 10 mg/m 2 ). All patients were housed in single rooms with HEPA filtered air and received prophylactic trimethoprim/sulfamethoxazole (320 mg/1600 mg) pretransplant and fluconazole, ciprofloxacine and acyclovir after transplant.
5,10 G-CSF was administered by continuous intravenous infusion (5 g/kg) after transplant until a neutrophil count Ͼ1000/l for 3 days was reached (detailed in Table 1 ). After engraftment, PCP prophylaxis was performed with either trimethoprim/ sulfamethoxazole twice weekly or in case of adverse reactions with monthly pentamidine (300 mg per inhalation). Immunoglobulin (10 g) were given every 10 days from days 0 to 100 post transplant.
Determination of leukocyte subsets
Peripheral cells were regularly quantified and automatically differentiated on an electric counter (STKS, Coulter, Krefeld, Germany). Lymphocyte subsets were determined every 2 months after transplant, depending on the availability of the patient. For immunophenotyping by flow cytometry, a whole blood lysing method was used with directly labeled primary antibodies, following the manufacturer's instructions. In brief, 100 l aliquots of whole blood collected in EDTA tubes (Sarstedt, Essen, Germany) were incubated for 15 min with appropriately diluted monoclonal antibody conjugates. The following combinations were used: CD14-FITC/CD45-PE (determination of lymphocytes, monocytes and granulocytes), CD3-FITC/CD4-PE (helper/inducer-T lymphocytes), CD3-FITC/CD8-PE (cytotoxic/suppressor T lymphocytes), CD3-FITC/CD16/ 56-PE (natural killer (NK) cells), CD19-PE (B lymphocytes); from February 1997 CD4-FITC/CD45RO-PE ('memory' helper/inducer T cells) and CD45RA-FITC/CD4-PE ('naive' helper/inducer T cells) were additionally evaluated. After addition of 2 ml lysing solution for 15 min, cells were washed once and measured within 2 h on a FACScan or FACS Calibur (all reagents were from Becton Dickinson, Heidelberg, Germany). Gat-ing of lymphocytes and estimation of the gated lymphocytes were performed according to the guidelines of the NIAID. 12 Absolute lymphocyte subset numbers were calculated by multiplication of the subset percentage and the lymphocyte number obtained from the differential. Cut-off for evaluation was 19 August 1997.
Determination of lymphocyte subsets and quantification of CD34
ϩ cells in grafts
The numbers of CD34 ϩ cells and lymphocyte subpopulations in leukapheresis products were determined as previously described. 9 BM was analyzed with the whole blood lysing method described above. Quantification of CD34 ϩ cells was performed by dual staining for FITC-CD45 and PE-CD34 (HPCA-2; Becton Dickinson) and appropriate gating on the blast region according to Haas et al. 13 
Statistical analysis
The observation period was restricted to the first 12 months after transplantation. All measurements of the lymphocyte subset parameters were transformed by the natural logarithm to obtain data showing symmetric distributions.
14 All calculations were based on these log transformed values. The influence of various patient characteristics known at time of transplantation on the reconstitution of lymphocyte subsets was analyzed: inclusion of MP in the GVHD prophylaxis, patient's CMV serostatus (IgG negative or positive), sex, age (Ͻ35 years vs older), disease status (first remission or first chronic phase vs all other advanced stages), diagnosis (acute leukemia (AL) vs CML vs other), inclusion of total body irradiation (TBI) in the conditioning regimen, application of G-CSF after transplantation, number of donor CD34 ϩ cells and number of donor CD3 ϩ cells transplanted (the latter two parameters were analyzed as continuous variables after log transformation). For the statistical analysis of the effect of these factors random coefficient growth curve models were fitted to the data. 15 A linear trend in the log transformed values of the leukocyte parameters over the first 12 months was assumed for each individual patient. Estimation and tests based on the maximum likelihood method were performed using the procedure MIXED in SAS Version 6.12. (SAS/STAT software) 16 with the assumption of a normal distribution with unstructured covariance matrix for the intercepts and slopes of the straight lines. Differences between groups were tested by including the respective variable and its interaction with time as fixed effects in the model. The estimated values at 2 and 6 months after transplantation were compared. This means that instead of comparing the parameters measured at each time interval as an isolated set of values, the evolution of the parameters of each patient over time was analyzed. All tests were two-sided with significance level ␣ = 0.05. No adjustment for multiple testing was performed.
The primary end-point was to compare lymphocyte subset reconstitution after the different transplantation modalities (PBPC34 vs PBPC vs BMT). There were imbalances of some variables among the transplantation groups, eg CMV IgG titer (only three of 12 positive patients in the PBPC34 group) and inclusion of steroids in the GVHD prophylaxis (none in the PBPC34 group and the majority of patients in the PBPC and BMT groups). Therefore, the observed differences and/or similarities among the groups may not directly be attributed to the transplantation regimen and the confounding factors need to be taken into account. This could not be performed by adjustment for these factors within multivariate models, because the imbalances were too extreme. The same problem exists for the interpretation of differences among groups defined by other factors such as CMV serostatus and the type of GVHD prophylaxis. Therefore, the influence of CMV serostatus and inclusion of steroids in GVHD prophylaxis was separately analyzed for the PBPC and BMT groups.
Results
Parameter distribution in the transplant groups
Analysis of the parameter distribution among the three transplant groups resulted in the following differences: CD34 ϩ enrichment of PBPC grafts resulted in a 264-fold depletion of CD3 ϩ T cells (median 0.53 ϫ 10 6 /kg body weight) compared with unselected PBPC grafts (140 ϫ 10 6 /kg). BMT grafts contained a median of 19 ϫ 10 6 cells/kg (detailed in Table 2 ). The number of /kg). The disease spectrum was more heterogeneous in the PBPC34 and PBPC groups compared with the BMT group. In addition, disease status was more favorable in the BMT group compared with the PBPC34 and PBPC groups (Table  1) . Patients in the PBPC34 group had received CsA only without steroids or MTX for GVHD prophylaxis because of the relative T cell depletion of the grafts. Positive CMV titers were found in only three of 12 patients in the PBPC34 group, while 10 of 20 and 10 of 15 patients were positive in the PBPC and BMT groups, respectively. There was a strong correlation between a positive CMV IgG titer before transplant and CMV reactivation (as defined by two consecutive positive PCR results) after transplant: while 18 of 23 patients with a positive serology reactivated, none of five patients with a positive donor and negative recipient serology and only one patient with a negative donor and recipient constellation turned CMV positive. All patients reactivated within the first 49 days after transplant. Antiviral treatment consisted of ganciclovir in 13 patients and foscarnet in six patients for a median of 22 days. A second course of treatment was instituted in three patients because of repeated positive PCR results for CMV. None of the patients developed clinical CMV disease with organ involvement as defined by Einsele et al. 17 
Lymphocyte subsets
Lymphocyte subsets were analyzed bimonthly after transplant. The evolution of T lymphocyte subsets in the various transplant groups is shown in Figure 1 . ϩ : 800-3600/l; CD3 ϩ 4 ϩ : 400-2500/l; CD3 ϩ 8 ϩ : 300-1000/l; CD19 ϩ : 120-600/l).
T lymphocytes (CD3 ϩ ):
The evolution of CD3 ϩ cells with respect to the three transplant groups was comparable over the first 12 months (Figure 1a) . The PBPC34 groupreceiving the lowest T cell numbers in the grafts -tended to be lower compared with the PBPC and BMT groups, especially within the first 6 months, however, this was not significant (estimated mean values of 405, 509 and 602/l CD3 ϩ T cells at 6 months in the PBPC34, PBPC and BMT groups, respectively). When analyzing the influence of T cell numbers contained in individual grafts (using the graft T cell number as a continuous variable) on T cell counts in the respective patients after transplant, there was a significant correlation after 2, but not after 6 months: an increase of one log of T cells/kg recipient body weight in the graft resulted in an estimated 1.3-fold increase of the T cell count 2 months after transplant, while the estimated increase was only 1.1-fold at 6 months.
Patients with a positive CMV IgG titer before transplant had significantly higher CD3 ϩ numbers than the CMV negative group (at 6 months 791 vs 340 cells/l, P Ͻ 0.0001; Figure 2 ). CD3 ϩ cell numbers of Ͼ800 cells/l (lower range of normal) were found in 15 patients during the first 12 months after transplantation and 13 of those were CMV IgG positive.
CD3
ϩ 4 ϩ lymphocytes: Absolute numbers of CD3 ϩ 4 ϩ cells were comparable in all three transplant groups during the first 12 months (135/l, 182/l and 198/l in the PBPC34, PBPC and BMT group at 6 months). Positive CMV serology before transplant resulted in higher CD3 ϩ 4 ϩ numbers (at 6 months: 226 vs 140 cells/l, P Ͻ 0.002). Normal CD3 ϩ 4 ϩ cell numbers (Ͼ400/l) were found in 11 patients during the first 12 months after transplant, nine of those were CMV seropositive. Subset analysis of naive and memory (CD4 ϩ 45RA ϩ vs CD4 ϩ 45RO ϩ ) was implemented in the panel only from February 1997 and was not considered for statistical analysis. However, CD4
ϩ 45RA ϩ cells were consistently lower than the CD4 ϩ 45RO ϩ subtype and appeared comparable among the three transplant groups.
ϩ 8 ϩ cells: There were no significant differences in all three transplant groups during the observation period (251/l, 275/l and 363/l in the PBPC34, PBPC and BMT group at 6 months). A positive CMV titer before transplant resulted in higher CD3 ϩ 8 ϩ cell numbers after transplant (519 vs 170 cells/l at 6 months; P Ͻ 0.0001). Patients, who had received TBI as part of the conditioning regimen (n = 10) had significantly higher CD3 ϩ 8 ϩ cell numbers than patients receiving chemotherapy only (at 6 months 578 cells/l for patients with TBI vs 244 cells/l, P Ͻ 0.01). Since the patient group receiving TBI was small and heterogeneous, this observation was not analyzed for other potentially confounding factors.
ϩ ratio remained Ͻ1 in all three transplant groups (except the BMT groups at 2 months) and was comparable among the three transplant groups. Positive CMV titers at transplantation went along with a lower CD3 ϩ 4 ϩ to CD3 ϩ 8 ϩ ratio (0.4 vs 0.8 at 6 months; P = 0.001).
Activated T lymphocytes (CD3
The number of activated T cells was comparable among the three transplant groups. Patients with a positive CMV serostatus had more activated T cells compared to seronegative patients (at 6 months 252 vs 102 cells/l; P Ͻ 0.001). Likewise, the number of activated T cells was higher when radiation was included in the conditioning regimen (at 6 months: 321 vs 133 cells/l; P Ͻ 0.01). This latter observation was not analyzed further for confounding factors.
B lymphocytes (CD19
ϩ ): B lymphocyte regeneration was faster in the PBPC34 groups as compared to both other groups (at 6 months 57, 21 and 17 cells/l in the PBPC34, PBPC and BMT group, respectively; P Ͻ 0.01). GVHD prophylaxis without MP was correlated with a higher number of B cells (53 vs 15 cells/l at 6 months, P Ͻ 0.0001). This correlation persisted only when the PBPC and the BMT groups (seven patients without steroids vs 28 patients with steroids) were analyzed (45 vs 15 cells/l at 6 months, P Ͻ 0.001). The B lymphocyte evolution of all patients, who did or did not receive MP as part of the GVHD regimen, irrespective of the transplant group, is shown in Figure 3 . At 12 months, when MP had been tapered off in most patients of the steroid group, B cell numbers appeared to be comparable.
NK cells (CD3
The number of NK cells appeared to be similar in all three transplant groups throughout. 
Clinical course
Within the observation period of 12 months after transplant, five, seven and three deaths had occurred in the PBPC34, the PBPC and BMT group, respectively. In the PBPC group there was one fatal pneumonia, in the BMT group two fatal infectious complications (one pneumococcal meningitis and one sepsis-like syndrome). The remaining deaths were due to relapse or persistence of disease except for one patient with adult respiratory distress syndrome (PBPC34 group) and one bronchiolitis obliterans (BMT group). The median follow-up after transplant for all patients was 7.9 (range 1.2-12 months), 9.1 (3.5-12) and 12 months (3.7-12) in the PBPC34, the PBPC and the BMT group.
The occurrence of severe acute GVHD (Ͼ grade II) was rare and nonfatal in all three groups (one patient with grade III in the PBPC34 group and one patient each with grade IV acute GVHD in the PBPC and BMT groups, respectively). Grade II GVHD was observed in three, five and four patients, respectively. The incidence of nonfatal bacterial and viral infections occurring 3-12 months after transplant in the PBPC34 groups was comparable to that in the PBPC and BMT groups: clinical bacterial infections, that were followed by at least 5 days of antibiotic treatment, occurred 21 times (seven patients), 44 (13 patients) and 28 times (nine patients) in the PBPC34, PBPC and BMT group, respectively. During the same observation period six episodes (in four patients) of localized viral infections (such as herpes zoster or herpes simplex of the oral cavity), were documented in the PBPC34 group, while there were 12 episodes (five patients) and seven episodes (five patients) in the PBPC and BMT groups, respectively. Of note, except for one generalized herpes zoster infection (in the BMT group) that could be controlled by antiviral treatment, no further opportunistic infection was observed. None of the patients developed EBV-associated lymphoproliferative disease.
Discussion
The feasibility of allogeneic peripheral blood progenitor cell transplantation has been shown recently. Potential advantages over conventional BM transplantation include avoidance of general anesthesia during graft harvest and possibly, a more rapid hematologic reconstitution. [1] [2] [3] [4] In order to minimize the potentially increased risk of GVHD because of the high T cell number contained in PBPC grafts, T cell depletion by CD34 ϩ selection has been used as a possible strategy. We, and others, have shown a rapid and long-lasting engraftment after transplantation with CD34 ϩ -selected PBPC comparable to unselected PBPC transplantation without severe acute GVHD. 5, 6 However, T cell depletion of more than two logs in the PBPC grafts is of concern, since transplantation with T cell-depleted allogeneic BM is associated with delayed immune reconstruction and consecutively an increased susceptibility for opportunistic infections. 7, 8 The data presented here provide preliminary evidence that CD34 ϩ selection did not significantly affect T lymphocyte evolution during the first year, when compared with unselected PBPC or BM grafts. The findings are limited, since the patient groups were divergent with respect to the disease status and treatment parameters (inclusion of MTX for GVHD prophylaxis and administration of G-CSF after transplant) and the confounding influence of these parameters on lymphocyte reconstitution cannot be entirely excluded. Although a higher number of T cells contained in the grafts correlated with higher T cell counts 2 months after transplant, this effect was not maintained at 6 months after transplant. Moreover, this correlation did not translate into significant differences in T cell evolution among the transplant groups during the 12 month observation period.
Furthermore, we found that a positive patient CMV titer before transplant was correlated with faster recovery of T lymphocytes, mainly due to an increase of CD3 ϩ cells, at day ϩ49 post transplant as an important risk factor for the development of fatal CMV disease. They reported no significant difference of the number of CD3 ϩ 4 ϩ cells of patients with or without asymptomatic reactivation of CMV. However, these analyses were limited to patients who had developed a CMV infection with organ involvement after transplantation from unrelated donors and are not comparable to those presented here, since none of our patients had CMV infection with organ involvement.
On the other hand, Li et al 19 suggest that antiviral treatment itself may affect lymphocyte reconstitution. They reported a delay in the appearance of CMV-specific T cell responses after allotransplantation in patients who had received ganciclovir continuously after transplant compared with patients without such treatment. Since in our study the higher T cell numbers of CMV seropositive vs seronegative patients were only observed later than 2 months after transplant, one might speculate that T cell regeneration is affected by both CMV reactivation and possibly by increased generation of T cells after cessation of antiviral treatment as a compensatory mechanism.
Recently, more rapid T lymphocyte reconstitution after PBPC allogeneic transplantation as opposed to BMT transplantation from matched related donors was reported. 20 In our patient group, neither CD3 ϩ 4 ϩ nor CD3 ϩ 8 ϩ counts were consistently higher in the PBPC group compared with the BMT group. Accordingly, the CD3 ϩ 4 ϩ to CD3 ϩ 8 ϩ ratio has never reached a value of Ͼ1 in any of the patient groups (except at 2 months in the BMT group). It remains unsolved at present whether different patient characteristics, such as disease status or CMV serostatus or a difference in the amount of transplanted T cells (140 ϫ 10 6 T cells/kg recipient body weight (present study) vs 701 ϫ 10 6 T cells/kg (Ottinger et al 20 ) ), accounts for these discrepancies.
B lymphocyte recovery in the PBPC34 group was faster compared with both other transplant groups. This is of interest since CD34 ϩ selection of the PBPC grafts resulted in a 100-fold depletion of B cells compared with unselected grafts, suggesting that the B lymphocytes contained in the grafts do not contribute to the B cell compartment after transplant. However, the faster regeneration is probably mainly due to the omission of MP as part of the GVHD prophylactic regimen in the PBPC34 group, since the inclusion of steroids was correlated with a delayed B lymphocyte recovery, independent of the type of graft ( Figure  3 ). This correlation is further supported by the observation that by the time when GVHD prophylaxis had been tapered off, the B cell numbers also normalized in most of the patients in the BMT and PBPC groups. Martínez et al 21 reported very low or undetectable B cell counts in their group of patients transplanted with PBPC34 grafts from matched related donors 4 months after transplant and whoin contrast to our patients -had received steroids as part of GVHD prophylaxis. Reports about B cell evolution after matched related BMT or PBPC and GVHD prophylaxis without steroids (CsA and MTX only) are divergent: a number of studies report a normalization of B lymphocyte numbers within the first 6 months after transplantation from matched related donors with either conventional or T celldepleted BM. 22, 23 Others reported a delayed normalization of B lymphocyte numbers beyond 11 months in adult patients after matched related BMT and PBPC 20 (CsA and MTX for GVHD prophylaxis) or children after T celldepleted BMT from matched or partially mismatched related donors. 18 Taken together, B lymphocyte reconstitution seems to be delayed by steroid treatment after transplant and, in the light of limited clinical benefit, further supports the notion that inclusion of steroids in the GVHD prophylaxis may not be beneficial. 24 The number of infectious events after transplant among the three transplant groups was comparable. However, because of the limited number of patients investigated, important differences cannot entirely be excluded.
In conclusion, our preliminary results suggest that quantitative lymphocyte reconstitution after transplantation with CD34 ϩ -selected PBPC was comparable to the reconstitution after transplantation with unmanipulated PBPC or conventional BM grafts and went along with a comparable prevalence of infectious complications. CMV serostatus of the recipient was found to be highly influential on T cell reconstitution and needs to be considered when evaluating T cell numbers after transplant. However, lymphocyte numbers by themselves -although predictive for opportunistic infections in certain clinical post transplant situations 8, 17 may yield limited clinically relevant information and more detailed investigations such as analysis of the T cell receptor repertoire and functional assessment may further help to identify patients at high risk for opportunistic infections. However, in light of the excellent engraftment with T celldepleted PBPC grafts, allogeneic transplantation with CD34
ϩ -selected PBPC grafts may offer a promising treatment alternative to T cell-depleted BM grafts and should be considered for further trials.
